SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer
Sponsor: David A. Clump, MD, PhD
A NA clinical study on Adenocarcinoma of the Pancreas, this trial is completed. The trial is conducted by David A. Clump, MD, PhD and has accumulated 12 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Dec 2021 — Dec 2022 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Mar 2021 — Dec 2021 [monthly]
Completed NA
Phase: PHASE2 → NA
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- David A. Clump, MD, PhD
For direct contact, visit the study record on ClinicalTrials.gov .